Medikamentöse Therapie 5 - Deutsche Gesellschaft für ...

5.5.12 Systemische Sklerose z 381
23. Lecomte T, Cavicchi M, Delchier JC (2000) Small bowel pseudo-obstruction revealing
in early scleroderma. Long-term efficacy of octreotide and erythromycin.
Gastroenterol Clin Biol 24:361–363
24. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes
MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH,
Ryan K, Sunderhaus J, Russell K, Rambharose J, Storb R, Furst DE (2002) Highdose
immunosuppressive therapy for severe systemic sclerosis: initial outcomes.
Blood 100:1602–1610
25. Medsger TA Jr, Lucas M, Wildy KS, Baker C (2001) D-penicillamine in systemic
sclerosis? Yes! Scand J Rheumatol 30:192–194
26. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos
PG (2002) Cyclophosphamide with low or high dose prednisolone
for systemic sclerosis lung disease. J Rheumatol 29:298–304
27. Parameswaran K, Purcell I, Farrer M, Holland C, Taylor IK, Keaney MP (1999)
Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic
sclerosis. Respir Med 93:75–78
28. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Iloprost
and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis.
Cochrane Database Syst Rev (2):CD000953
29. Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A (2000) Prazosin
for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database
Syst Rev (2):CD000956
30. Rook AH, Freundlich B, Jegasothy BV, Perze MI, Barr WG, Jimenez SA, Rietschel
RL, Wintroub B, Kahaleh MB, Varga J (1992) Treatment of systemic sclerosis
with extracorporeal photochemotherapy: results of a multicenter trial. Arch Dermatol
128:337–346
31. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A,
Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary
hypertension. N Engl J Med 346:896–903
32. Russell ML, Schachter RK (1988) Cyclosporin treatment of scleroderma (PSS).
Arthritis Rheum 31:S51
33. Schnabel A, Reuter M, Gross WL (1998) Intravenous pulse cyclophosphamide in
the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis
Rheum 41:1215
34. Sharada B, Kumar A, Kakker R, Adya CM, Pande I, Uppal SS, Pande JN, Sunderam
KR, Malaviya AN (1994) Intravenous dexamethasone pulse therapy in diffuse
systemic sclerosis. A randomized placebo-controlled study. Rheumatol Int
14:91–94
35. Shor R, Halabe A (2002) New trends in the treatment of scleroderma renal crisis.
Nephron 92:716–718
36. Seibold JR, Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE,
Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME,
Hsu V, Erikson M, Hannigan J, Harkonen WS, Sanders ME (2000) Recombinant
human relaxin in the treatment of scleroderma. A randomized, placebo-controlled
trial. Ann Intern Med 132:871–879
37. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Stange C (1993)
Cyclophosphamide and low-dose prednisone therapy in patients with systemic
sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844
38. Steen VD, Medsger TA Jr, Rodnan DP (1982) D-penicillamine therapy in progressive
systemic sclerosis (scleroderma). An Intern Med 97:652–658